{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T17:27:23Z","timestamp":1784654843366,"version":"3.55.0"},"reference-count":34,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":652,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int. J. Cancer"],"published-print":{"date-parts":[[2014,5,15]]},"DOI":"10.1002\/ijc.28579","type":"journal-article","created":{"date-parts":[[2013,10,31]],"date-time":"2013-10-31T13:22:57Z","timestamp":1383225777000},"page":"2322-2329","source":"Crossref","is-referenced-by-count":43,"title":["Preclinical trial of a new dual mTOR inhibitor, MLN0128, using renal cell carcinoma tumorgrafts"],"prefix":"10.1002","volume":"134","author":[{"given":"Alexandre","family":"Ingels","sequence":"first","affiliation":[{"name":"Department of Urology; Stanford University School of Medicine; Stanford CA"},{"name":"Department of Urology; Centre Hospitalier Universitaire du Kremlin-Bic\u00eatre; Kremlin-Bic\u00eatre France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongjuan","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Urology; Stanford University School of Medicine; Stanford CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan E.","family":"Thong","sequence":"additional","affiliation":[{"name":"Department of Urology; Stanford University School of Medicine; Stanford CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Saar","sequence":"additional","affiliation":[{"name":"Department of Urology; Stanford University School of Medicine; Stanford CA"},{"name":"Department of Urology and Pediatric Urology; University of Saarland; Homburg\/Saar Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maija P.","family":"Valta","sequence":"additional","affiliation":[{"name":"Department of Urology; Stanford University School of Medicine; Stanford CA"},{"name":"Division of Medicine; Turku University Hospital and University of Turku; Turku Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosalie","family":"Nolley","sequence":"additional","affiliation":[{"name":"Department of Urology; Stanford University School of Medicine; Stanford CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Santos","sequence":"additional","affiliation":[{"name":"Department of Urology; Stanford University School of Medicine; Stanford CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna M.","family":"Peehl","sequence":"additional","affiliation":[{"name":"Department of Urology; Stanford University School of Medicine; Stanford CA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2013,11,18]]},"reference":[{"key":"10.1002\/ijc.28579-BIB0001|ijc28579-cit-0001","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1002\/cncr.22677","article-title":"Prognostic relevance of the mTOR pathway in renal cell carcinoma: implications for molecular patient selection for targeted therapy","volume":"109","author":"Pantuck","year":"2007","journal-title":"Cancer"},{"key":"10.1002\/ijc.28579-BIB0002|ijc28579-cit-0002","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.juro.2006.08.076","article-title":"Activation of the mTOR signaling pathway in renal clear cell carcinoma","volume":"177","author":"Robb","year":"2007","journal-title":"J Urol"},{"key":"10.1002\/ijc.28579-BIB0003|ijc28579-cit-0003","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.ctrv.2012.12.015","article-title":"Differentiating mTOR inhibitors in renal cell carcinoma","volume":"39","author":"Pal","year":"2013","journal-title":"Cancer Treat Rev"},{"key":"10.1002\/ijc.28579-BIB0004|ijc28579-cit-0004","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.critrevonc.2013.02.006","article-title":"mTOR inhibitors in advanced renal cell carcinomas: from biology to clinical practice","volume":"88","author":"Barthelemy","year":"2013","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1002\/ijc.28579-BIB0005|ijc28579-cit-0005","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.hoc.2011.04.008","article-title":"mTOR inhibitors in advanced renal cell carcinoma","volume":"25","author":"Voss","year":"2011","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1002\/ijc.28579-BIB0006|ijc28579-cit-0006","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1158\/0008-5472.CAN-05-2925","article-title":"mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt","volume":"66","author":"O'Reilly","year":"2006","journal-title":"Cancer Res"},{"key":"10.1002\/ijc.28579-BIB0007|ijc28579-cit-0007","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/S1470-2045(09)70240-2","article-title":"Resistance to targeted therapy in renal-cell carcinoma","volume":"10","author":"Rini","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1002\/ijc.28579-BIB0008|ijc28579-cit-0008","doi-asserted-by":"crossref","first-page":"3733","DOI":"10.1038\/onc.2010.139","article-title":"Targeting mTOR: prospects for mTOR complex 2 inhibitors in cancer therapy","volume":"29","author":"Sparks","year":"2010","journal-title":"Oncogene"},{"key":"10.1002\/ijc.28579-BIB0009|ijc28579-cit-0009","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/nm.2091","article-title":"Effective and selective targeting of leukemia cells using a TORC1\/2 kinase inhibitor","volume":"16","author":"Janes","year":"2010","journal-title":"Nat Med"},{"key":"10.1002\/ijc.28579-BIB0010|ijc28579-cit-0010","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/nature10912","article-title":"The translational landscape of mTOR signalling steers cancer initiation and metastasis","volume":"485","author":"Hsieh","year":"2012","journal-title":"Nature"},{"key":"10.1002\/ijc.28579-BIB0011|ijc28579-cit-0011","article-title":"Tissue slice grafts of human renal cell carcinoma: an authentic preclinical model with high engraftment rate and metastatic potential","author":"Thong","year":"2013","journal-title":"Urol Oncol"},{"key":"10.1002\/ijc.28579-BIB0012|ijc28579-cit-0012","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1182\/blood-2002-10-3241","article-title":"A new xenograft model for graft-versus-host disease by intravenous transfer of human peripheral blood mononuclear cells in RAG2-\/- gammac-\/- double-mutant mice","volume":"102","author":"Rijn","year":"2003","journal-title":"Blood"},{"key":"10.1002\/ijc.28579-BIB0013|ijc28579-cit-0013","doi-asserted-by":"crossref","first-page":"229","DOI":"10.2353\/ajpath.2010.090821","article-title":"Tissue slice grafts: an in vivo model of human prostate androgen signaling","volume":"177","author":"Zhao","year":"2010","journal-title":"Am J Pathol"},{"key":"10.1002\/ijc.28579-BIB0014|ijc28579-cit-0014","doi-asserted-by":"crossref","first-page":"3970","DOI":"10.1158\/0008-5472.CAN-06-3822","article-title":"Specific growth rate versus doubling time for quantitative characterization of tumor growth rate","volume":"67","author":"Mehrara","year":"2007","journal-title":"Cancer Res"},{"key":"10.1002\/ijc.28579-BIB0015|ijc28579-cit-0015","doi-asserted-by":"crossref","first-page":"230","DOI":"10.4161\/cbt.23294","article-title":"Antiproliferative effect of a novel mTOR inhibitor temsirolimus contributes to the prolonged survival of orthotopic esophageal cancer-bearing mice","volume":"14","author":"Nishikawa","year":"2013","journal-title":"Cancer Biol Ther"},{"key":"10.1002\/ijc.28579-BIB0016|ijc28579-cit-0016","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1158\/1535-7163.MCT-11-0907","article-title":"Modulation of Akt\/mTOR signaling overcomes sunitinib resistance in renal and prostate cancer cells","volume":"11","author":"Makhov","year":"2012","journal-title":"Mol Cancer Ther"},{"issue":"Suppl","key":"10.1002\/ijc.28579-BIB0017|ijc28579-cit-0017","article-title":"Clinical pharmacokinetics (PK) and translational PK-pharmacodynamic (PD) modeling and simulation to predict antitumor response of various dosing schedules to guide the selection of a recommended phase II dose (RP2D) and schedule for the investigational agent MLN0128","volume":"31","author":"Patel","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1002\/ijc.28579-BIB0018|ijc28579-cit-0018","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1038\/leu.2012.276","article-title":"Efficacy of the investigational mTOR kinase inhibitor MLN0128\/INK128 in models of B-cell acute lymphoblastic leukemia","volume":"27","author":"Janes","year":"2013","journal-title":"Leukemia"},{"key":"10.1002\/ijc.28579-BIB0019|ijc28579-cit-0019","doi-asserted-by":"crossref","first-page":"11988","DOI":"10.1073\/pnas.1310230110","article-title":"Myc and mTOR converge on a common node in protein synthesis control that confers synthetic lethality in Myc-driven cancers","volume":"110","author":"Pourdehnad","year":"2013","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1002\/ijc.28579-BIB0020|ijc28579-cit-0020","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1007\/s10549-012-2298-8","article-title":"Investigational drug MLN0128, a novel TORC1\/2 inhibitor, demonstrates potent oral antitumor activity in human breast cancer xenograft models","volume":"136","author":"Gokmen-Polar","year":"2012","journal-title":"Breast Cancer Res Treat"},{"key":"10.1002\/ijc.28579-BIB0021|ijc28579-cit-0021","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1111\/j.1432-0436.2007.00263.x","article-title":"Inhibition of monoamine oxidase A promotes secretory differentiation in basal prostatic epithelial cells","volume":"76","author":"Zhao","year":"2008","journal-title":"Differentiation"},{"key":"10.1002\/ijc.28579-BIB0022|ijc28579-cit-0022","doi-asserted-by":"crossref","first-page":"34495","DOI":"10.1074\/jbc.C800170200","article-title":"Differential dependence of hypoxia-inducible factors 1 alpha and 2 alpha on mTORC1 and mTORC2","volume":"283","author":"Toschi","year":"2008","journal-title":"J Biol Chem"},{"key":"10.1002\/ijc.28579-BIB0023|ijc28579-cit-0023","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.ccr.2008.10.016","article-title":"HIF-alpha effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma","volume":"14","author":"Gordan","year":"2008","journal-title":"Cancer Cell"},{"key":"10.1002\/ijc.28579-BIB0024|ijc28579-cit-0024","doi-asserted-by":"crossref","first-page":"857","DOI":"10.2174\/156800912802429265","article-title":"A comprehensive overview of targeted therapy in metastatic renal cell carcinoma","volume":"12","author":"Mihaly","year":"2012","journal-title":"Curr Cancer Drug Targets"},{"key":"10.1002\/ijc.28579-BIB0025|ijc28579-cit-0025","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1056\/NEJMoa066838","article-title":"Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma","volume":"356","author":"Hudes","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1002\/ijc.28579-BIB0026|ijc28579-cit-0026","doi-asserted-by":"crossref","first-page":"2995","DOI":"10.2174\/092986711796391651","article-title":"ATP-competitive inhibitors of mTOR: an update","volume":"18","author":"Schenone","year":"2011","journal-title":"Curr Med Chem"},{"key":"10.1002\/ijc.28579-BIB0027|ijc28579-cit-0027","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S1097-2765(02)00636-6","article-title":"Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control","volume":"10","author":"Loewith","year":"2002","journal-title":"Mol Cell"},{"key":"10.1002\/ijc.28579-BIB0028|ijc28579-cit-0028","doi-asserted-by":"crossref","first-page":"7401","DOI":"10.1038\/sj.onc.1209099","article-title":"Regulation of the Akt kinase by interacting proteins","volume":"24","author":"Du","year":"2005","journal-title":"Oncogene"},{"key":"10.1002\/ijc.28579-BIB0029|ijc28579-cit-0029","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.ceb.2009.10.007","article-title":"mTOR and cancer: many loops in one pathway","volume":"22","author":"Efeyan","year":"2010","journal-title":"Curr Opin Cell Biol"},{"key":"10.1002\/ijc.28579-BIB0030|ijc28579-cit-0030","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1158\/1541-7786.MCR-13-0212","article-title":"Dual inhibition of PI3K and mTOR mitigates feedback-loop pAkt activation to improve tamoxifen response in breast cancer cells","volume":"11","author":"Chen","year":"2013","journal-title":"Mol Cancer Res"},{"key":"10.1002\/ijc.28579-BIB0031|ijc28579-cit-0031","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1038\/sj.onc.1209990","article-title":"Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism","volume":"26","author":"Wan","year":"2007","journal-title":"Oncogene"},{"key":"10.1002\/ijc.28579-BIB0032|ijc28579-cit-0032","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.eururo.2011.10.007","article-title":"Meta-analysis of clear cell renal cell carcinoma gene expression defines a variant subgroup and identifies gender influences on tumor biology","volume":"61","author":"Brannon","year":"2012","journal-title":"Eur Urol"},{"key":"10.1002\/ijc.28579-BIB0033|ijc28579-cit-0033","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1177\/1947601909359929","article-title":"Molecular stratification of clear cell renal cell carcinoma by consensus clustering reveals distinct subtypes and survival patterns","volume":"1","author":"Brannon","year":"2010","journal-title":"Genes Cancer"},{"key":"10.1002\/ijc.28579-BIB0034|ijc28579-cit-0034","doi-asserted-by":"crossref","first-page":"897","DOI":"10.2217\/fon.10.50","article-title":"Genetic heterogeneity and chromatin modifiers in renal clear cell carcinoma","volume":"6","author":"Staller","year":"2010","journal-title":"Future Oncol"}],"container-title":["International Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fijc.28579","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/ijc.28579","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T16:42:17Z","timestamp":1625157737000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ijc.28579"}},"subtitle":["Evaluating mTOR inhibitors using RCC tumorgrafts"],"short-title":[],"issued":{"date-parts":[[2013,11,18]]},"references-count":34,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2014,5,15]]}},"URL":"https:\/\/doi.org\/10.1002\/ijc.28579","relation":{},"ISSN":["0020-7136"],"issn-type":[{"value":"0020-7136","type":"print"}],"subject":[],"published":{"date-parts":[[2013,11,18]]}}}